Budget Impact of Emicizumab for Routine Prophylaxis of Bleeding Episodes in Patients With Hemophilia A With Inhibitors.
Sign Up to like & getrecommendations! Published in 2021 at "Value in health regional issues"
DOI: 10.1016/j.vhri.2021.07.003
Abstract: OBJECTIVES To examine the budget impact of emicizumab as prophylactic therapy in reducing the frequency of bleeding episodes in patients with hemophilia A with inhibitors in Malaysia. METHODS A budget impact model was built to… read more here.
Keywords: bleeding episodes; budget impact; budget; prophylaxis ... See more keywords
Breakthrough bleeding episodes in pediatric severe hemophilia a patients with and without inhibitors receiving emicizumab prophylaxis: a single-center retrospective review
Sign Up to like & getrecommendations! Published in 2022 at "Pediatric Hematology and Oncology"
DOI: 10.1080/08880018.2021.2004269
Abstract: Abstract Emicizumab has been widely used for prophylaxis in patients with hemophilia A (HA) of all ages, with or without factor VIII inhibitors. Data on emicizumab efficacy are certainly significant; however, protection against bleeding is… read more here.
Keywords: bleeding episodes; emicizumab prophylaxis; single center; breakthrough bleeding ... See more keywords
Cost‐effectiveness of emicizumab vs bypassing agents in the prevention of bleeding episodes in haemophilia A patients with anti‐FVIII inhibitors in France
Sign Up to like & getrecommendations! Published in 2020 at "Haemophilia"
DOI: 10.1111/hae.14129
Abstract: The development of an anti‐FVIII inhibitor is the most serious complication of haemophilia A occurring in up to 30% of severe haemophilic patients. The current management of haemophilia A with inhibitor uses bypassing agents (BPA)… read more here.
Keywords: bleeding episodes; patients anti; prevention bleeding; anti fviii ... See more keywords